Different anti-BCMA CAR T-cell products have been developed over recent years and several clinical trials have shown impressive response rates to anti-BCMA CAR T-cell therapy in patients with relapsed refractory multiple myeloma (19–21). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.